A prospective study on clinical, serological and genetic factors of IgG4 - Related Disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00006025

Enrollment

370

Registered

2014-03-26

Start date

2014-03-27

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K85.01

Interventions

Group 1: Patient cohort: Blood sampling for determination of possible HLA associations in IgG4-RD Group 2: Control group (healthy people): Blood sampling to use as control for HLA associations.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Definite, probable or possible diagnosis of IgG4-RD according to published criteria (Umehara H et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012 Feb;22(1):21-30) and exclusion of differential diagnoses

Exclusion criteria

Exclusion criteria: IgG4-RD not confirmed

Design outcomes

Primary

Measure	Time frame
HLA class II genotypes in IgG4-RD as compared to the general population,	—

Secondary

Measure	Time frame
Evaluation of single nucleotide polymorphisms (CTLA4, TNF-alpha, FCRL3), assessment of laboratory values of immunological relevance, molecular biological examination of cytokines and chemokines, analysis of autoantibody profiles, characterization of PBMC subpopulations, evaluation of demographic, clinical and quality of life parameters as determined by SF36.	—

Countries

Austria, Germany, Italy

Contacts

Public ContactJochen Zwerina

Ludwig Boltzmann-Institut für Osteologieim Hanusch-Krankenhaus der WGKK undUnfallkrankenhaus Meidling der AUVA1. Medizinische Abteilung, Hanusch-Krankenhaus

jochen.zwerina@osteologie.at+43 1 91021 86921

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026